Ampreloxetine Funding (Tables)

12 Months Ended

Dec. 31, 2022

Ampreloxetine Funding.

Schedule of future royalty payment contingencies

(In thousands)
Beginning balance at July 20, 2022	$	—
Consideration allocated, less transaction costs of $0.5 million		24,464
Interest accretion		974
Balance at December 31, 2022	$	25,438